undamentalytics Newsletter
Sign in

Oncolytics Biotech Inc (ONCY) stock

Add to watchlist

Add holding +

NASDAQ: ONCY Nasdaq Biotechnology Next results ~November 16, 2026

Oncolytics Biotech Inc is a US-listed company in the biotechnology industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders10 buying, 0 selling14 purchases and 0 sales by directors and officers, last 12 monthsInsider trades
  • Funds71 adding, 2 cuttingOf 7 active managers that changed their stake, 6 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Next results ~November 16, 2026 (estimated)

Current signal Results well short of expectations: Reported earnings per share missed the analysts' consensus estimate by 47% in the quarter to 2026-06-30.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Oncolytics Biotech Inc's latest figures clears our strength thresholds.

Things to watch

  • Volatile shares. Over the past year the shares showed annualised volatility of 82% and a beta of 1.7 against the S&P 500.

Latest results

Earnings per share
-$0.11 against an average estimate of -$0.08: missed by 47.0%
Next report
November 16, 2026; average EPS estimate -$0.08

Oncolytics Biotech's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-7.0%
  • 1 week-14.9%
  • 1 month-36.5%
  • This year-54.0%
  • 1 year-66.4%
  • 5 years-81.2%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Announcement
  3. Announcement
  4. Announcement
  5. Announcement
  6. Announcement
  7. Announcement
  8. Announcement
  9. Announcement
  10. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Oncolytics Biotech Inc valuation models and calculator

No model value for Oncolytics Biotech Inc at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Valuation models

We value Oncolytics Biotech Inc as an operating company, with every model that fits that kind of business. Cost of equity 9.4%: the 10-year Treasury yield (4.9%) plus a beta of 0.98 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no twelve-month earnings or share count in the filings yet
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: no twelve-month earnings or share count in the filings yet
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: no twelve-month earnings or share count in the filings yet
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. — Does not apply: no twelve-month earnings or share count in the filings yet
Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. — No model applies: the filings don’t yet support a value.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Oncolytics Biotech Inc with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 16, 2026, after the close. Analysts expect revenue of $0 and EPS of −$0.08 (range −$0.08 to −$0.07) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.38 +9% — 0%
Next −$0.28 +26% — 0%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +2.1% on 90 days ago. In the last 30 days, 0 analysts raised Oncolytics Biotech Inc's forecast and 1 cut it.

Consensus EPS forecast Oncolytics Biotech Inc, last 90 days
−$0.40 −$0.30 −$0.20 −$0.10 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.37 Current fiscal year, 60 days ago: −$0.37 Current fiscal year, 30 days ago: −$0.37 Current fiscal year, 7 days ago: −$0.38 Current fiscal year, Now: −$0.38 −$0.38 Next fiscal year, 90 days ago: −$0.34 Next fiscal year, 60 days ago: −$0.34 Next fiscal year, 30 days ago: −$0.34 Next fiscal year, 7 days ago: −$0.34 Next fiscal year, Now: −$0.34 −$0.34

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.37−$0.34
60 days ago −$0.37−$0.34
30 days ago −$0.37−$0.34
7 days ago −$0.38−$0.34
Now −$0.38−$0.34

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.08 −$0.11 −47.0%
Mar 2026 −$0.06 −$0.11 −83.1%
Sept 2025 −$0.07 −$0.14 −108.2%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

6 analysts, Oct 2026
Buy583%
Hold117%
Sell00%

Monthly trend

  1. Oct 20263216
  2. Sep 20263216
  3. Aug 20263216
  4. Jul 20263216

Counts of recommendations published by analysts covering Oncolytics Biotech Inc, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
7.0%
of tradable shares
Days to cover
6.53
at average volume
Short interest, 1 month
+4%
to October 15, 2026
Held by institutions
9%
of shares
Held by insiders
1.7%
of shares
Employees
29
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
ONCY−42%+17%−17%−33%−4%−54%
Industry peers (median)−35%−57%−18%−28%−5%−26%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
ONCY25%42%33%25%42%46%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
ONCY−70%−58%−62%−47%−66%−69%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 3, 2015: 96% from January 10, 2018 to June 5, 2025. Getting back needed a 2347% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$0.40 – $1.27
From 52-week high
−68.5%
vs 50-day average
−39.3%
vs 200-day average
−53.5%
Volatility (1 year)
82%
Beta vs S&P 500
1.69

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms . Generated November 3, 2026. Definitions in our methodology.

Who owns it

Funds buying and selling
Reported value
$3.7M
Institutions reporting
75
Shares held vs prior quarter
▲ 358.3%
Positions opened / closed
71 / 1

Top buyers and sellers, Q2 2026: 71 institutions bought and 2 sold ; the biggest buyer was Xtx Topco Ltd (+261K shares) and the biggest seller Marshall Wace, LLP (−114K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Marshall Wace, LLP $708,082 745K 19.0% ▼ 13.3%
Xtx Topco Ltd $247,832 261K 6.6% New
Seeds Investor LLC $245,365 258K 6.6% New
International Assets Investment Management, LLC $181,275 201K 4.9% New
Connective Capital Management, LLC $176,408 186K 4.7% New
Goldman Sachs Group Inc $161,386 170K 4.3% New
Tocqueville Asset Management L.P. $139,635 147K 3.7% New
Everhart Financial Group, Inc. $133,840 141K 3.6% New
Susquehanna International Group, LLP $127,409 134K 3.4% New
Pfg Investments, LLC $121,872 128K 3.3% New
HRT Financial LP $119,000 126K 3.2% New
Invesco Ltd. $96,125 101K 2.6% New

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Oncolytics Biotech Inc's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $363,232 14 trades by 10 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $363,232 net buying
Insider Date Trade Shares Price Value
Kelly Jared Chief Executive Officer March 12, 2026 Buy 5,050 $0.96 $4,848
Parsons James T. Director March 11, 2026 Buy 10,000 $1.03 $10,300
Seizinger Bernd R. Director February 12, 2026 Buy 40,000 $0.85 $34,000
Andrews Patricia S Director February 12, 2026 Buy 35,400 $0.86 $30,444
Kelly Jared Chief Executive Officer February 12, 2026 Buy 29,500 $0.84 $24,780
Hagerman Allison VP, Product Development February 12, 2026 Buy 10,000 $0.83 $8,300
Brown Deborah Margaret Director February 12, 2026 Buy 25,000 $0.85 $21,250
Heineman Thomas Charles Chief Medical Officer February 12, 2026 Buy 12,132 $0.83 $10,070
Pisano Wayne Director February 12, 2026 Buy 30,000 $0.84 $25,200
Look Kirk Chief Financial Officer February 12, 2026 Buy 12,000 $0.84 $10,080
Kelly Jared Chief Executive Officer February 11, 2026 Buy 5,600 $0.84 $4,704
Aromando Andrew Chief Business Officer February 11, 2026 Buy 29,600 $0.86 $25,456

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Recent SEC filings

Data status

When each part of this page on Oncolytics Biotech Inc was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Oncolytics Biotech Inc in brief

What does Oncolytics Biotech Inc do?
Oncolytics Biotech Inc is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Oncolytics Biotech Inc's stock ticker?
Oncolytics Biotech Inc trades under the ticker ONCY on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Oncolytics Biotech Inc's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Marshall Wace, LLP, Xtx Topco Ltd and Seeds Investor LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Are insiders buying or selling Oncolytics Biotech Inc stock?
Over the last 12 months, Oncolytics Biotech Inc's directors and officers reported 14 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
When is Oncolytics Biotech Inc's next earnings date?
Around November 16, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Oncolytics Biotech Inc announces its own schedule.